Mean Platelet Volume/platelet Count Ratio Can Predict the Recurrence-free Survival Rate of Patients After Complete Resection of Gastrointestinal Stromal Tumors

Overview

Journal Front Oncol

Specialty Oncology

Date 2024 Nov 25

PMID 39582542

Authors

Xinlian Du

Xinxin Zang

Hanbo Zhang

Lijia Liu

Ying Xu

Xuedong Li

Ruishu Mou

Haitao Xu

Jiuxin Zhu

Rui Xie

Affiliations

Soon will be listed here.

Abstract

Purpose: The aim of this study is to compare mean platelet volume/platelet count ratio (PVPR) and other indicators' predictive abilities. Simultaneously, a new nomogram for predicting recurrence-free survival (RFS) after gastrointestinal stromal tumors (GISTs) R0 resection was developed.

Methods: From January 2010 to July 2019, 295 patients with GIST who were operated on at Harbin Medical University Cancer Hospital were retrospectively reviewed. With a 4-year RFS as the end point, using the Kaplan-Meier methods and log rank test, and then conducting Cox regression analysis, we compared and identified meaningful indicators for predicting prognosis. Finally, a nomogram was developed and validated using calibration curves.

Results: The receiver operating characteristic curve indicated that a cutoff point of 0.044 was the ideal threshold for PVPR, and patients were divided into a high-PVPR group (≤0.044) and a low-PVPR group (>0.044). Kaplan-Meier curves suggested that PVPR>0.044 had obvious associations with better RFS (p < 0.001). In accordance with multivariate analysis, PVPR (>0.044 vs. ≤0.044) (p = 0.005), National Institutes of Health (NIH) risk category (p < 0.001), and Ki-67 (p = 0.005) were the independent prognostic indicators of RFS. Tumor size, gastrointestinal bleeding, mitotic index, NIH risk category, CD34, and Ki-67 all exhibited an obvious correlation with PVPR (all p < 0.05). The nomogram's probability of concordance was 0.823, indicating that the nomogram predictions were well calibrated.

Conclusion: In GISTs, RFS can be independently predicted by PVPR. Patients with higher PVPR have better RFS. The nomogram including PVPR could be used to assist clinical treatment decision-making.

References

Cananzi F, Minerva E, Sama L, Ruspi L, Sicoli F, Conti L . Preoperative monocyte-to-lymphocyte ratio predicts recurrence in gastrointestinal stromal tumors. J Surg Oncol. 2018; 119(1):12-20. DOI: 10.1002/jso.25290. View

Unk M, Novakovic B, Novakovic S . Molecular Mechanisms of Gastrointestinal Stromal Tumors and Their Impact on Systemic Therapy Decision. Cancers (Basel). 2023; 15(5). PMC: 10001062. DOI: 10.3390/cancers15051498. View

Goettsch W, Bos S, Breekveldt-Postma N, Casparie M, Herings R, Hogendoorn P . Incidence of gastrointestinal stromal tumours is underestimated: results of a nation-wide study. Eur J Cancer. 2005; 41(18):2868-72. DOI: 10.1016/j.ejca.2005.09.009. View

Cho S, Yang J, You E, Kim B, Shim J, Lee H . Mean platelet volume/platelet count ratio in hepatocellular carcinoma. Platelets. 2012; 24(5):375-7. DOI: 10.3109/09537104.2012.701028. View

Xin Y, Zhang X, Li Y, Yang Y, Chen Y, Wang Y . A Systemic Inflammation Response Index (SIRI)-Based Nomogram for Predicting the Recurrence of Early Stage Hepatocellular Carcinoma After Radiofrequency Ablation. Cardiovasc Intervent Radiol. 2021; 45(1):43-53. DOI: 10.1007/s00270-021-02965-4. View

Schisterman E, Faraggi D, Reiser B, Hu J . Youden Index and the optimal threshold for markers with mass at zero. Stat Med. 2007; 27(2):297-315. PMC: 2749250. DOI: 10.1002/sim.2993. View

Blay J, Kang Y, Nishida T, von Mehren M . Gastrointestinal stromal tumours. Nat Rev Dis Primers. 2021; 7(1):22. DOI: 10.1038/s41572-021-00254-5. View

DeMatteo R, Ballman K, Antonescu C, Corless C, Kolesnikova V, von Mehren M . Long-term results of adjuvant imatinib mesylate in localized, high-risk, primary gastrointestinal stromal tumor: ACOSOG Z9000 (Alliance) intergroup phase 2 trial. Ann Surg. 2013; 258(3):422-9. PMC: 4041735. DOI: 10.1097/SLA.0b013e3182a15eb7. View

Cao X, Cui J, Yu T, Li Z, Zhao G . Fibrinogen/Albumin Ratio Index Is an Independent Prognosis Predictor of Recurrence-Free Survival in Patients After Surgical Resection of Gastrointestinal Stromal Tumors. Front Oncol. 2020; 10:1459. PMC: 7462001. DOI: 10.3389/fonc.2020.01459. View

10.

Lu Z, Li R, Cao X, Liu C, Sun Z, Shi X . Assessment of Systemic Inflammation and Nutritional Indicators in Predicting Recurrence-Free Survival After Surgical Resection of Gastrointestinal Stromal Tumors. Front Oncol. 2021; 11:710191. PMC: 8350728. DOI: 10.3389/fonc.2021.710191. View

11.

Cai H, Li X, Wang S . Prognostic value of fibrinogen and D-dimer-fibrinogen ratio in resectable gastrointestinal stromal tumors. World J Gastroenterol. 2018; 24(44):5046-5056. PMC: 6262247. DOI: 10.3748/wjg.v24.i44.5046. View

12.

Suzuki-Inoue K . Platelets and cancer-associated thrombosis: focusing on the platelet activation receptor CLEC-2 and podoplanin. Blood. 2019; 134(22):1912-1918. DOI: 10.1182/blood.2019001388. View

13.

Li W, Peng Q, Lin Y, Wan W, Zeng X, Sun X . [A model to predict the recurrence of middle-high risk gastrointestinal stromal tumors based on preoperative fibrinogen and peripheral blood inflammatory indexes]. Zhonghua Wei Chang Wai Ke Za Zhi. 2020; 23(9):896-903. DOI: 10.3760/cma.j.cn.441530-20200613-00355. View

14.

Omar M, Tanriverdi O, Cokmert S, Oktay E, Yersal O, Pilanci K . Role of increased mean platelet volume (MPV) and decreased MPV/platelet count ratio as poor prognostic factors in lung cancer. Clin Respir J. 2016; 12(3):922-929. DOI: 10.1111/crj.12605. View

15.

Gu J, Zhang X, Wang Z, Cui R, Zhang J, Jia Y . Simplified nomograms based on platelet-associated models for survival prediction in Asian hepatocellular carcinoma patients after surgery. Surg Oncol. 2019; 30:131-138. DOI: 10.1016/j.suronc.2019.07.008. View

16.

Korniluk A, Koper-Lenkiewicz O, Kaminska J, Kemona H, Dymicka-Piekarska V . Mean Platelet Volume (MPV): New Perspectives for an Old Marker in the Course and Prognosis of Inflammatory Conditions. Mediators Inflamm. 2019; 2019:9213074. PMC: 6501263. DOI: 10.1155/2019/9213074. View

17.

Casali P, Abecassis N, Aro H, Bauer S, Biagini R, Bielack S . Gastrointestinal stromal tumours: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018; 29(Suppl 4):iv68-iv78. DOI: 10.1093/annonc/mdy095. View

18.

Li J, Ye Y, Wang J, Zhang B, Qin S, Shi Y . Chinese consensus guidelines for diagnosis and management of gastrointestinal stromal tumor. Chin J Cancer Res. 2017; 29(4):281-293. PMC: 5592117. DOI: 10.21147/j.issn.1000-9604.2017.04.01. View

19.

Detopoulou P, Panoutsopoulos G, Mantoglou M, Michailidis P, Pantazi I, Papadopoulos S . Relation of Mean Platelet Volume (MPV) with Cancer: A Systematic Review with a Focus on Disease Outcome on Twelve Types of Cancer. Curr Oncol. 2023; 30(3):3391-3420. PMC: 10047416. DOI: 10.3390/curroncol30030258. View

20.

Becker E, Ozcan G, Wu G . Primary Hepatic Extra-gastrointestinal Stromal Tumors: Molecular Pathogenesis, Immunohistopathology, and Treatment. J Clin Transl Hepatol. 2023; 11(4):942-948. PMC: 10318283. DOI: 10.14218/JCTH.2022.00173. View